Develops gene therapies for rare cardiovascular diseases.
Jun 2026Revenue $0.00/yrExpenses $192M/yr
No trendCash runway ≈ 1.7 years from Jun 2026
Figures by year
When will Rocket Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.00 and expenses $192M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $232M | −$232M |
| Dec 2024 | $0.00 | $273M | −$273M |
| Dec 2023 | $0.00 | $260M | −$260M |
| Dec 2022 | $0.00 | $224M | −$224M |
| Dec 2021 | $0.00 | $167M | −$167M |
| Dec 2020 | $0.00 | $134M | −$134M |
| Dec 2019 | $0.00 | $76.2M | −$76.2M |
| Dec 2018 | $0.00 | $71.2M | −$71.2M |
| Dec 2017 | $0.00 | $19.8M | −$19.8M |
| Dec 2016 | $0.00 | $7.57M | −$7.57M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.